Epigenomics gets Euros1.1 million for cancer screening technology:
This article was originally published in Clinica
The German Ministry for Education and Research (BMBF) has given Berlin firm Epigenomics Euros1.1m ($1.3m) to help support a three-year project to design and develop new techniques for high-throughput early cancer screening based on DNA methylation, a natural "switch" that controls gene expression. "This research will further add to the competitive advantages offered by our DNA methylation based technologies," said Kurt Berlin, the firm's chief scientific officer. Due to start in May 2004, the project aims to develop new methods for detecting cancer early that will complement and further expand Epigenomics' pipeline of methylation based products for diagnostic and pharmacodiagnostic applications, the company said.